Q-omics provides the consensus-scored POLR2G profile across patient tissues and cancer cell-line models. POLR2G expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, POLR2G is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, POLR2G protein abundance shows 22,672 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, BLCA, and GBM as cancer lineages where POLR2G shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR2G — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR2G survival associations across molecular data types. POLR2G RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR2G RNA expression–survival associations across cancer types. High POLR2G expression shows unfavorable associations in ACC, HNSC, KICH, LIHC and CESC, but favorable associations in UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for POLR2G RNA expression.
This table summarizes POLR2G tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for POLR2G. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR2G shows lower tumor expression in KICH and higher tumor expression in BLCA, HNSC, KIRC, COAD and LIHC. The BLCA box plot shows higher POLR2G RNA expression in tumor versus normal tissue (log2 FC = +1.043, t-test p < 0.001).
This table shows molecular features associated with POLR2G in patient tissues and cancer cell lines. In patient samples, POLR2G shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR2G RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
